7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $868M | $159M | 77.2% | 24.0% | $348M | $164M | $753M |
| 2024 | $715M | $145M | 78.1% | 26.7% | $219M | $179M | $453M |
| 2023 | $582M | $129M | 79.2% | 33.0% | $219M | $194M | $312M |
| 2022 | $438M | $181M | 80.9% | 27.4% | $144M | $192M | $244M |
| 2021 | $305M | $35M | 81.8% | 28.7% | $98M | $192M | $234M |
| 2020 | $160M | -$37M | 82.6% | 10.6% | -$3M | $194M | $229M |
| 2019 | $6M | -$152M | 73.7% | -2433.8% | -$76M | $98M | $24M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $215M | $32M | 79.3% | 17.3% | — | $159M | $589M |
| Dec '25 | $244M | $22M | 71.9% | 15.8% | $126M | $164M | $753M |
| Sep '25 | $239M | $51M | 75.1% | 27.3% | $109M | $169M | $647M |
| Jun '25 | $200M | $40M | 81.0% | 24.0% | $79M | $172M | $546M |
| Mar '25 | $185M | $46M | 82.7% | 30.4% | $34M | $176M | $489M |
| Dec '24 | $201M | $49M | 73.0% | 27.7% | $75M | $179M | $453M |
| Sep '24 | $186M | $46M | 77.0% | 33.2% | $70M | $183M | $387M |
| Jun '24 | $173M | $12M | 81.4% | 12.4% | $42M | $186M | $317M |
| Mar '24 | $155M | $38M | 82.2% | 33.7% | $31M | $190M | $333M |
| Dec '23 | $168M | $27M | 74.4% | 23.9% | $77M | $194M | $312M |
| Sep '23 | $160M | $38M | 79.8% | 40.3% | $63M | $197M | $325M |
| Jun '23 | $134M | $34M | 81.4% | 34.9% | — | $191M | $317M |
| Mar '23 | $119M | $29M | 82.6% | 33.9% | — | $192M | $288M |
| Dec '22 | $128M | $49M | 79.0% | 37.1% | $27M | $192M | $244M |
| Sep '22 | $117M | $88M | 80.4% | 10.2% | $55M | $192M | $261M |
| Jun '22 | $107M | $24M | 82.3% | 30.9% | $34M | $192M | $237M |
| Mar '22 | $85M | $21M | 82.8% | 32.3% | $29M | $192M | $224M |
| Dec '21 | $91M | $23M | 80.5% | 31.4% | $38M | $192M | $234M |
| Sep '21 | $81M | -$10M | 81.9% | 26.1% | $30M | $192M | $190M |
| Jun '21 | $74M | $14M | 82.8% | 31.6% | $18M | $196M | $160M |
How the market has priced HRMY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Harmony Biosciences Holdings, Inc.'s revenue has grown 40.3% per year. These are computed facts, not advice.
As of FY2025, Harmony Biosciences Holdings, Inc. reported $164M of total debt against $753M of cash; operating income covered interest expense 14×.
In FY2025, gross margin was 77.2%, operating margin 24.0%, and net margin 18.3%.
As of Jun '26, Harmony Biosciences Holdings, Inc. traded at a price-to-earnings ratio of about 12.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.